Why Is 4D Molecular Therapeutics Stock Gaining Monday? - 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to an 87% cut in treatment burden.

Raccontata dabenzinga.com